文献速递肿瘤 PET/CT神经核医学

优化神经内分泌肿瘤患者的生长抑素受体显像:99mTc-HYNICTOC SPECT/SPECT/CT与68Ga-DOTATATE PET/CT对临床管理的影响比较

Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
PubMed 文献 · Clin Nucl Med · 2017-01-01

这项前瞻性研究纳入68例组织学证实的播散性神经内分泌肿瘤患者,比较99mTc-HYNICTOC SPECT/SPECT/CT与68Ga-DOTATATE PET/CT在灵敏度、特异度及对临床决策影响方面的差异。68Ga-DOTATATE的灵敏度、特异度、阳性预测值、阴性预测值和准确率分别为100%、85%、97%、100%和97%,均高于99mTc-HYNICTOC的82%、69%、92%、47%和79%。68Ga-DOTATATE使23例(34%)患者的临床管理发生改变。

要点

  • 68Ga-DOTATATE PET/CT灵敏度100%、准确率97%,均高于99mTc-HYNICTOC的82%和79%。
  • 68Ga-DOTATATE检出546个病灶,99mTc-HYNICTOC检出218个病灶(P < 0.0001)。
  • 68Ga-DOTATATE使23/68例(34%)患者的临床管理发生改变。

核心结论

  • 68Ga-DOTATATE检测神经内分泌肿瘤的灵敏度高于99mTc-HYNICTOC。
  • 68Ga-DOTATATE在检出亚厘米骨、淋巴结和肝转移方面优于99mTc-HYNICTOC。
  • 68Ga-DOTATATE PET/CT使三分之一患者的临床决策发生改变。

研究设计与样本

  • 前瞻性研究纳入68例播散性、组织学证实的神经内分泌肿瘤患者(30男、38女,年龄56.4 ± 13.5岁)。
  • 所有既往行99mTc-HYNICTOC(Tektrotyd;POLATOM,Otwock,波兰)检查的患者均接受68Ga-DOTATATE PET/CT检查。
  • 两种检查按患者和按病灶进行比较。

主要发现

  • 68Ga-DOTATATE与99mTc-HYNICTOC的灵敏度为100% vs 82%,特异度为85% vs 69%,阳性预测值为97% vs 92%,阴性预测值为100% vs 47%,准确率为97% vs 79%。
  • 58例患者结果一致(49/68两种检查均阳性,9/68两种检查均阴性)。
  • 10/68例患者为68Ga-DOTATATE阳性而99mTc-HYNICTOC阴性。
  • 99mTc-HYNICTOC检出218个病灶,68Ga-DOTATATE检出546个病灶(P < 0.0001)。
  • 68Ga-DOTATATE在骨和淋巴结、肝、肠、胰腺检出更多病灶,对亚厘米异常的灵敏度高于99mTc-HYNICTOC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The presence of somatostatin receptors in neuroendocrine tumors allows visualization with radiolabeled somatostatin analogs in vivo. The aim of this prospective study was to compare somatostatin receptor imaging using Tc-HYNICTOC with Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) with respect to sensitivity, specificity, and impact upon clinical decision making. METHODS: Sixty-eight patients (30 men, 38 women; aged 56.4 ± 13.5 years) with disseminated, histologically proven neuroendocrine tumor were enrolled. All patients with previous Tc-HYNICTOC (Tektrotyd; POLATOM, Otwock, Poland) underwent Ga-DOTATATE PET/CT. Both examinations were compared on a per-patient and per-lesion basis. RESULTS: The sensitivity, specificity, positive and negative predictive values, and accuracy of Ga-DOTATATE and Tc-HYNICTOC were 100% versus 82%, 85% versus 69%, 97% versus 92%, 100% versus 47%, and 97% versus 79%, respectively.Concordant results were observed in 58 patients (49/68 positive on both Ga-DOTATATE and Tc-HYNICTOC and 9/68 negative in both examinations). Ten of 68 patients had Ga-DOTATATE-positive, Tc-HYNICTOC-negative studies. Two hundred eighteen lesions were detected using Tc-HYNICTOC, compared with 546 lesions using Ga-DOTATATE (P < 0.0001). Ga-DOTATATE detected a higher number of lesions in bone and lymph nodes, liver, intestine, and pancreas and had a higher sensitivity for subcentimeter abnormalities than Tc-HYNICTOC. Ga-DOTATATE led to management change in 23 (34%) of 68 patients. CONCLUSIONS: Ga-DOTATATE has a higher sensitivity than Tc-HYNICTOC for the detection of neuroendocrine tumors. Ga-DOTATATE proved superior to Tc-HYNICTOC in detecting subcentimeter skeletal, lymph node, and liver metastases. Ga-DOTATATE PET/CT changed clinical decision making in one third of patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kunikowska J, Lewington V, Krolicki L, et al. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Clin Nucl Med. 2017. PMID: 29076910. doi:10.1097/RLU.0000000000001877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。